// App-Quantinova.ai

1695 : Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in β-Thalassemia with Luspatercept: Longitudinal Results of the BELIEVE Trial

Researchers

Presenter

  • Ali T. Taher

Principal Investigators

  • Vip Viprakasit

  • Olivier Hermine

  • John B. Porter

  • Antonio Piga

  • Kevin H.M. Kuo

  • Thomas D. Coates

  • Ersi Voskaridou

  • Abderrahim Khelif

  • Antonis Kattamis

  • Jeevan K. Shetty

  • George Zhang

  • Yu (Olivia) Tian

  • Dimana Miteva

  • Tatiana Zinger

  • Derek Tang

  • Jay T. Backstrom

  • Maria Domenica Cappellini

Medical Centers

  • Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon

  • Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

  • Imagine Institute, INSERM U1163, University of Paris, Paris, France

  • Department of Haematology, Tenon University Hospital, Assistance Publique Hopitaux de Paris, Paris, France

  • University College London and University College London Hospitals NHS Foundation Trust, London, United Kingdom

  • Dept of Clinical and Biological Sciences, University of Turin, Turin, Italy

  • Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Division of Hematology, Department of Medicine, University of Toronto,Toronto, ON,Canada

  • Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA

  • UCLA School of Medicine, Los Angeles, CA

  • Thalassemia and Sickle Cell Center ,Laiko General Hospital,Athens,Grecia

  • Farhat Hached Teaching Hospital, Sousse University,Sousse,Tunisie

  • First Department of Radiology, Aretaieion Hospital, National and Kapodistrian University of Athens, Athens, Greece

  • Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Acceleron Pharma, Cambridge, MA

  • Fondazione IRCCS Ca' Granda Maggiore Hospital, University of Milan, Milan, Italy

Locations

  • Lebanon

  • Thailand

  • France

  • United Kingdom

  • Italy

  • Canada

  • United States

  • Greece

  • Tunisia

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Thalassemia

Biomarkers

  • Red Blood Cells

Drug/Treatment

  • luspatercept

Outcome

  • N/A


Study Design

  • Randomized

  • Cross Over

  • Open Label

Phase

  • III

Study Id's

  • NCT02604433

Sponsors

  • N/A

Result

  • N/A